Hepatitis B virus (HBV) persists with global and virus-specific T-cell dysfunction, without Tcell based correlates of outcomes. To determine if γδT-cells are altered in HBV infection relative to clinical status, we examined the frequency, phenotype and function of peripheral blood Vδ1 + and Vδ2 + γδT-cells by multi-parameter cytometry in a clinically diverse North American cohort of chronic hepatitis B (CHB), acute hepatitis B (AHB) and uninfected control subjects. We show that circulating γδT-cells were comprised predominantly of CD3 hi
CD4
-Vδ2
+ γδT-cells with frequencies that were 2-3 fold higher among Asian than non-Asian Americans and inversely correlated with age, but without differences between CHB, AHB and control subjects. However, compared to control subjects, CHB was associated with increased Tbet 
Introduction
Hepatitis B virus (HBV) is an important human pathogen with a global impact in morbidity and mortality. As HBV is generally non-cytopathic, liver disease pathogenesis is largely immune-mediated with rapid progression to cirrhosis and cancer in some and minimal disease progression in others [1] [2] [3] . A critical role for conventional T-cells in viral clearance and liver disease has been shown in animal models and inferred in patients [4] [5] [6] [7] [8] [9] . However, in patients with chronic hepatitis B (CHB), both HBV-specific and global T-cells are functionally suppressed due to continued antigenic stimulation, inflammation and the induction of multiple regulatory pathways [4] [5] [6] [7] [8] [9] [10] [11] [12] . Furthermore, there are no distinct T-cell based immune signatures for the dynamic clinical and virological phases of CHB [10] . These findings also raised the possiblity for alternate mechanisms beyond conventional T-cells in CHB pathogenesis.
In this context, γδT-cells are highly effector-like non-conventional CD3 + T-cells with T-cell receptors (TCR) comprised of γ and δ chains [13, 14] ) and features of both adaptive and innate immune cells [15] [16] [17] [18] . Among human γδT-cell subsets, Vδ2 + γδT-cells that co-express Vγ9
TCR with a CD3 hi CD4 -phenotype are the major subset of circulating γδT-cells with frequencies of 2-4% in healthy adults, whereas Vδ1 + and Vδ3 + γδT-cells are detected in tissue com-subfamily 3, member A1 (BTN3A1) plays a key role in activating Vδ2 + γδT-cells by binding phosphoantigens that accumulate in stressed, transformed or infected cells [16, [25] [26] [27] [28] . Furthermore, γδT-cells participate in lymphoid stress surveillance by sensing cellular stress associated with infection, inflammation and transformation [29, 30] . Because γδT-cells can be rapidly activated to lyse infected or malignant cells and to produce effector cytokines such as IFNγ and TNF or IL17 [15] [16] [17] [18] , there are ongoing efforts to harness γδT-cells in immunotherapy against cancer and viral infections [31] [32] [33] [34] [35] . Relevant for microbial pathogenesis, increased Vδ2 + γδT-cell frequency has been reported in infections with intracelluar pathogens such as mycobacterium tuberculosis, salmonella or malaria [17] . A protective role for γδT-cells in viral infections has been suggested by: increased Vδ2 + γδT-cells in elite HIV controllers [36] , reduced Vδ2 + γδT-cell frequency associated with poor HIV-related outcomes [37] [38] [39] , and Vδ1 + γδT-cell expansion associated with the resolution of cytomegalovirus (CMV) infection [40] [41] [42] . A role for γδT-cells in HBV immunobiology was first suggested in experimentally HBV-infected chimpanzees with hepatic induction of γδTCR-associated genes leading to viral clearance [43] . Findings in patients with CHB have been more conflicting [44] [45] [46] [47] [48] , with reduced Vδ2 + γδT-cell frequencies in one study [44] but not another [48] . Both pathogenic and regulatory roles have been suggested by enhanced cytolytic potential reported in patients with HBV-associated acute-on-chronic liver failure [46] and CD8 T-cell exhaustion by inducing myeloid-derived suppressor cells in a mouse model [49] .
Here, we compared the frequency, phenotype and function of circulating γδT-cells in human subjects with CHB relative to those with acute hepatitis B (AHB) and uninfected normal control subjects (NC), initially hypothesizing that their frequency and/or function will be reduced in CHB with increased disease activity. Contrary to our hypothesis, we found that γδT-cells are preserved in circulating frequencies in CHB and AHB, with distinct innate-like phenotype and/or effector function compared to uninfected control subjects. In particular, compared to uninfected controls, AHB subjects showed weaker IFNγ/TNF responses in Vδ2 + γδT-cells that improved with the resolution of AHB whereas CHB subjects showed with preserved IFNγ/TNF responses in Vδ2
+ γδT-cells. Furthermore, in CHB, IFNγ/TNF responses to brief PMA/Ionomycin stimulation in Vδ2 + γδT-cells correlated inversely with serum alanine aminotransferase (ALT), with persistent deficit in patients with hepatitis ALT flares compared to those without flares. These findings provide new insights to γδT-cells with relevance to HBV pathogenesis.
Methods

Study subjects
Adults with CHB and acute hepatitis B (AHB) were enrolled into the Hepatitis B Research Network (HBRN) Adult Cohort Study sponsored by the National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK), as previously described [50] . Subjects with hepatic decompensation, liver cancer, liver transplant, current hepatitis B antiviral therapy, known HIV co-infection and inability or unwillingness to attend follow-up visits were excluded. A subset of HBRN participants (215 CHB, 12 AHB) were recruited into the ancillary Immunology Study with additional informed consent for immunology blood draws from the following clinical centers: Toronto (University of Toronto), Dallas (University of Texas Southwestern), San Francisco (University of California San Francisco, California Pacific Medical Center); Richmond (Virginia Commonwealth University); Seattle (Virginia Mason Medical Center and University of Washington); Minnesota (University of Minnesota and Mayo Clinic), Boston (Beth Israel Deaconness Medical Center, Massachusetts General Hospital) and Chapel Hill (University of North Carolina), as previously described [10] . Among 215 CHB subjects initially enrolled into the Immunology Study, we included 189 in this study, excluding 10 who were found to be on antiviral therapy at the time of immunology blood draw and 16 without concurrent serum alanine aminotransferase (ALT) level. Thirty-four HBsAg-negative normal control subjects (NC) were recruited from the HBRN Immunology Center in Philadelphia (University of Pennsylvania and Corporal Michael J. Crescenz Veterans Affairs Medical Center), Toronto and Dallas, including 29 with a history of prior HBV vaccination. NC subjects were recruited based on the absence of known liver disease, autoimmune disease, immunosuppression and active medical conditions that preclude large volume research blood draws. They were also negative for serum HBsAg, antibody to hepatitis C virus (anti-HCV) and antibody to human immunodeficiency virus (anti-HIV).
As shown in Table 1A , CHB, NC and AHB groups did not differ significantly in age or sex distribution, although the CHB group showed a marked Asian predominance consistent with the overall HBRN adult cohort [10, 50] . Asians with CHB showed higher HBV DNA levels with higher prevalence of positive hepatitis B e antigen (HBeAg) status and infection with HBV genotypes B or C, compared to Non-Asians with CHB ( Table 1B) . As for liver biopsy 
Ethics statement
The study received approval by the institutional review board or equivalent committee(s) for each of the centers participating in patient recruitment as stated above and previously described [10] 
Clinical grouping of HBV-infected subjects
Clinical phase of each HBV-infected subject was assigned based on medical history and laboratory results as previously described as immune tolerant (IT), HBeAg + immune active (IA+), HBeAg -immune active (IA-) or inactive carrier (IC) status [10] . ALT levels were normalized by the upper limits of normal (ULN) for ALT (30 U/L for men and 20 U/L for women) as ALT/ULN ratio. ALT flare was defined by ALT/ULN �10 (ALT 300 U/L for males, 200 U/L for females). Subjects identified with an ALT flare were asked to return for additional immunology blood draw within 1-4 weeks of meeting criteria for ALT flare and again within 12-24 weeks from initial hepatitis flare or before starting antiviral therapy if not resolved. Acute hepatitis B (AHB) was defined by acute ALT elevation in the presence of HBsAg and IgM antibody to hepatitis B core antigen (IgM anti-HBc) without a previous history of HBsAg positivity. The Immunology Center personnel were blinded to clinical parameters while conducting immune assays.
Peripheral blood mononuclear cells (PBMC)
PBMC were isolated from blood drawn in lavender-top plasma tubes (ethylenediaminetetraacetic acid or EDTA as additive) using Ficoll-Histopaque (Sigma Chemical Co., St Louis, MO) density centrifugation and resuspended in complete media with 10% human male AB serum as described [10] . PBMC isolation was performed within 24 hours of blood draw.
Antibodies and reagents
Fluorescent monoclonal antibodies (mAbs) were purchased as follows: anti-CD8, anti-CD56, anti-CD94, anti-NKG2D, anti-CTLA-4 and anti-TNF from BD Bioscience (San Jose, CA); anti-CD127, anti-CD3, anti-CD28 and anti-Eomesodermin (Eomes) from eBioscience (San Diego, CA); anti-PD-1, anti-Tbet and anti-IFNγ from BioLegend (San Diego, CA); anti-NKG2A from R&D Systems (Minneapolis, MN); anti-Vδ1 TCR (clone REA173) from Miltenyi Biotec (San Diego, CA); anti-Vδ2 TCR (clone B6), anti-Vγ9 TCR (clone B3) and pan-γδ TCR (clone B1) from BioLegend (San Diego, CA). Dead cells were excluded using Aqua dead cell stain kit (Life Technologies). The phycoerythrin-or allophycocyanin-labeled CD1d tetramers were kindly provided by the NIH Tetramer Facility at Emory University (Atlanta, GA).
Immunophenotyping
Cells were stained with fluorescent antibodies according to the manufacturer's instructions, acquired by FACSCanto (BD Biosciences, San Jose, CA) and analyzed with FlowJo (Tree Star Inc., San Carlos, CA). Magnetic beads coated with anti-mouse antibodies were used for compensation calculation (BD Biosciences, San Jose, CA) as described previously [51, 52] . CD3 hi CD4 -T-cell frequency and phenotype in 189 CHB (including 39 with hepatitis flare), 34 NC and 12 AHB participants were examined by staining freshly isolated PBMC with a multi-parameter screening T-cell panel that included fluorescent antibodies for CD3, CD4, CD8, PD-1, CTLA-4, CD28 and CD127 [10] . More detailed γδT-cell analyses were performed with secondary FACS panels in 70 subjects with available cryopreserved PBMC (36 CHB, 27 NC and 7 AHB participants) with the inclusion of CD16, CD56, CD161, NKG2D, NKG2A, CD158a and/or CD94. Among the 36 CHB subjects, 14 with ALT flares (CHB-F) were first examined within 1-4 weeks of ALT flare. PBMCs from a second time point (at least 2 months from the initial time point) were also analyzed in 7 CHB-F and in 7 AHB subjects. Examination for γδTCR subtype (Vδ1, Vδ2, Vγ9), phenotype (T/NK markers), effector molecules (perforin, granzyme B) and transcription factor expression (Tbet, Eomes) was conducted directly ex-vivo. In select cases with available lymphocytes (11 CHB, 7 NC), PBMC were stained with metal-conjugated antibodies and acquired by CyTOF II as described [53, 54] [58] with 0.5 million PBMC/well stimulated for 23 hours with: 1) media with 50 U/ml recombinant interleukin-2 (rIL2); 2) 20 microM zoledronic acid (Zol) (Sigma Aldrich) with 50 U/ml rIL2; 3) 1 nanoM (E)-4-hydroxy-3-methylbut-2-enyl pyrophosphate (HMBPP) (Sigma Aldrich) with 50 U/ml rIL2; 4) 10 ng/ml PMA and 200 ng/ml Ionomycin. For 23 hour stimulation, 10 mcg/ml Brefeldin A (eBioscience) and 1X GolgiStop (BD Biosciences) were added after 16 hours to maximize intracellular signal [58] . In control assays comparing 23 ) γδT-cell frequencies in CHB compared to NC or AHB group (Fig 1E) . However, since Asian Americans were highly enriched in CHB compared to NC or AHB group in our study (84% vs 47% vs 0%, p<0.001, Table 1A), we compared γδT-cell frequencies between Asian and non-Asian American subgroups in CHB and NC groups. As shown in Fig  1F, ) γδT-cell frequencies (Fig 1G) consistent with lower γδT-cell frequencies reported in older persons [59, 60] . There were no differences between males or females (median %CD3 hi CD4 -/CD3: males 2.4% vs females 2.7%, p = .80). Finally, there were no significant correlations between γδT-cell frequencies and serum HBV DNA or alanine aminotransferase (ALT) levels in CHB subjects (Fig 1H) . Thus, circulating γδT-cell frequencies were not altered by HBV infection in our study, although Vδ2 + γδT-cell frequency was significantly impacted by host factors such as race/ethnicity and age.
Circulating γδT-cells display an innate phenotype with the expression of both T and NK regulatory markers that are distinctly altered in AHB and CHB Consistent with innate characteristics reported for γδT-cells [15] , γδT-cells were more enriched in expression of NK markers compared to total CD3 + T-cells. For example, Vδ2 + γδT-cells expressed more CD56 and CD16 compared to total CD3 + T-cells, without significant differences between CHB, NC and AHB groups (Fig 2A, left 
CD4
-γδT-cell frequencies were compared in 189 CHB (158 Asians, 31 Non-Asians), 34 NC (16 Asians, 18 Non-Asians) and 12 AHB (12 Non-Asians) subjects in freshly isolated PBMCs. Frequency differences between CHB, NC and AHB groups were calculated by non-parametric Kruskal Wallis (k = 3). P-values below 0.05 were considered significant and shown in red font. 
-cells (gray bars) relative to Vδ1
+ γδT-cells (blue bars) or Vδ2 + γδT-cells (red bars) in CHB, NC and AHB groups, with error bars indicating 25% and 75% interquartile ranges. CD56 and CD16 expression levels were examined in 35 CHB, 18 NC and 7 AHB subjects, whereas CD161 expression was examined in 33 CHB, 27 NC and 4 AHB subjects. Expression levels between the cell subsets within individual subject were compared by matched pair signed-rank test. Comparisons between CHB, NC and AHB groups were made with Kruskal Wallis (k = 3). Histogram on the right bottom show overlay of CD3 (gray shade), Vδ1
+ γδT-cells (blue line) or Vδ2 + γδT-cells (red line). (S2A and S2B Fig) .
Tbet/Eomes expression is enriched in circulating Vδ1
Notably, Tbet/Eomes expression in Vδ1 + and Vδ2 + γδT-cells correlated with their expression of NK markers CD56 and CD16, while CD161 expression correlated with Tbet/Eomes expression in Vδ1 + γδT-cells but not Vδ2 + γδT-cells (Fig 3D, S3A Fig) Circulating gammadelta T cells in acute and chronic hepatitis B CD107a mobilization or IL17 expression (Fig 5B) . These differences in CD3 (Fig 5D) + γδT-cells to both Zol and HMBPP (as well as IFNγ response to PMA/Ionomycin) compared to NC or CHB subjects, but without significant differences between CHB and NC subjects detected in early responses to PMA/Ionomycin (Fig 5A and 5B) . However, late IFNγ/ TNF responses to pAg in Vδ2 + γδT-cells showed significant positive correlations with their NKG2A/CD94 expression (Fig 6C) , similar to early IFNγ/TNF responses to PMA/Ionomycin (Fig 5C) 
CD4
-T-cells from NC (white bars) and AHB (orange bars) subjects. Error bars indicate 25% and 75% interquartile ranges. P-values between 3 groups were determined by Kruskal Wallis test (k = 3), followed by further two-way comparisons by Mann Whitney U for initial p-value below 0.05. P-values below 0.05 were considered significant and highlighted in red font for convenience. Gating strategy is shown in S4 Fig. https://doi.org/10.1371/journal.ppat.1007715.g005
Circulating gammadelta T cells in acute and chronic hepatitis B ALT flares in CHB are clinically relevant events associated with necroinflammatory changes in the liver [71] [72] [73] . Given the inverse associations between serum ALT and early IFNγ/TNF responses in γδT-cells to PMA/Ionomycin stimulation in CHB, CHB subjects with and without a recent hepatitis flare (ALT/ULN �10 within a month of immune analyses) were further compared for IFNγ/TNF responses in γδT-cells. As shown in Fig 8A, Circulating gammadelta T cells in acute and chronic hepatitis B (Fig 8B) . As for late IFNγ/TNF responses in Vδ2 + γδT-cells to pAg or PMA/Ionomycin stimulation, comparisons between CHB IT, IA or IC subgroups could not be made due to small sample sizes precluding meaningful statistical comparisons (e.g. only 2 IT and 3 IC), although no significant differences were detected between CHB subgroups with and without ALT flares (Fig 8C) or with and without circulating HBeAg (Fig 8D) . (Fig 8F) . Thus, compared to CHB Non-Flare subjects, CHB γδT-cells, 7 CHB F subjects with available cryopreserved PBMC were examined at a second time point (T2) at least 2 months (9-41 weeks) after the initial evaluation (T1) for frequency, phenotype and early IFNγ responses to PMA/Ionomycin (Fig 9A) . Seven AHB subjects with available PBMC at similar time frame were also examined for comparison (Fig 9B) . As expected, ALT levels declined after the initial evaluation in all subjects, whereas HBV DNA levels declined in most but not all subjects. However, the overall circulating frequency and Tbet expression in Vδ2 + γδT-cells did not differ significantly between T1 and T2 in CHB Flare or AHB subjects. Furthermore, early IFNγ responses to PMA/Ionomycin in Vδ2 + γδT-cells did not change significantly between T1 and T2 for CHB Flare subjects (median %IFNγ + : T1 46.9% vs T2 25.9%, p = .13) and in fact declined in 5/7 subjects. By contrast, IFNγ expression in Vδ2
+ γδT-cells increased in 6/7 AHB subjects (median %IFNγ+: T1 49.5% vs T2 60.2%, p = .029). Conversely, %IFNγ -TNFα -double-negative Vδ2 + γδT-cells declined significantly in AHB but not CHB Flare subjects. We further examined the dynamic evolution in serum ALT (red diamond) and HBV DNA (green diamond) relative to %IFNγ + /Vδ2
+ γδT-cells (blue circle) in CHB Flare and AHB subjects (Fig 9C) . As shown, resolution of ALT flare was not associated with increased %IFNγ Collectively, we show that γδT-cells are preserved in circulating frequency but altered with distinct innate phenotype and effector function in acute and chronic HBV infection with relevance to clinical status.
Discussion
While T-cells play a critical role in disease pathogenesis and viral clearance in acute HBV infection, their role in chronic HBV infection is less clear due to functional impairment with the induction of multiple immune regulatory pathways [4] [5] [6] [7] [8] [9] [10] [11] [12] . As γδT-cells are non-conventional T-cells that participate in lymphoid stress surveillance [29, 30] and microbial pathogenesis [17] , we asked if γδT-cells contribute to HBV pathogenesis. To this end, we examined the frequency, phenotype and effector function of circulating γδT-cells in a North American cohort of HBV-infected and uninfected subjects. Our findings show that γδT-cells are preserved in circulating frequency regardless of HBV infection, with CD3 hi CD4 -Vδ2 + γδT-cells as the predominant subset. We further show distinct phenotypic and functional characteristics of γδT-cells in acute and chronic HBV infection with potential pathogenetic relevance. Contrary to altered γδT-cell frequencies reported in HIV, CMV and several other intracellular pathogens such as mycobacterium tuberculosis [17, [36] [37] [38] [39] , circulating γδT-cell frequencies did not differ significantly between HBV-infected and uninfected subjects in our study. Our findings differ from reports associating γδT-cell frequencies with clinical status of CHB [44] [45] [46] [47] [48] . For example, reduced Vδ2 + γδT-cell frequency was associated with severe HBV-associated liver disease in several studies of Chinese subjects with CHB [44-46]. Conversely, asymptomatic HBV carriers with low HBV DNA and ALT showed increased circulating Vδ1 + and Vδ2 + γδT-cell frequencies compared to controls in a study from Ireland with mixed African, Caucasian and Asian subjects [48] . Unlike previous studies, we examined North Americans well-preserved liver function without decompensation [10, 50] . Although most of our CHB subjects consisted of Asian Americans, our findings persisted when Asian and nonAsian Americans were examined separately. We also confirmed circulating γδT-cell Americans displayed 2-3 fold higher circulating Vδ2 + γδT-cell frequency compared to NonAsian Americans. These differences were not due clinical or virological status of CHB as they were also detected in uninfected controls. They were not associated with HIV or CMV coinfection, since HIV-infected or immunosuppressed subjects were excluded in our study and CMV infection generally impacts Vδ1 + (not Vδ2
To our knowledge, differential γδT-cell frequency between Asian and Non-Asian Americans has not been reported, although greater Vδ2 + γδT-cell frequency was described in Caucasian compared to African
Americans [74] . The inverse association between age and Vδ2 + (but not Vδ1 + ) γδT-cell frequency was consistent with previous reports [59, 60] . The underlying mechanisms that govern γδT-cell homeostasis and their clinical implications are not well-defined, although both environmental factors (e.g. diet, infection, microbes) as well as genetics are shown to impact human immune system [75] [76] [77] . In fact, Vδ2 +
Vδγ9
+ γδT-cells showed greater heritability than other innate-line T-cells such as Vδ1 + γδT-cells and NKT-cells, although innate immune traits were influenced more by environment whereas adaptive immune traits were impacted more by genetic [78] . In any case, the marked differences in Vδ2 + γδT-cell frequency between Asians and Non-Asians suggest that race/ethnicity must be considered in clinical studies involving Vδ2 + γδT-cells, including immunotherapy [31] [32] [33] [34] [35] .
Another key finding in our study is the distinct innate phenotype with increased Tbet/ Eomes expression in circulating γδT-cells in AHB and CHB compared to uninfected control subjects. (Fig 3C) . Furthermore, AHB subjects displayed more CD56 and CD16 expression in Vδ1 + (but not Vδ2 + ) γδT-cells compared to NC and CHB subjects (Fig 2A) . On the other hand, CHB subjects showed significantly greater Tbet expression and Tbet hi Eomes dim phenotype in CD3 hi CD4 -Vδ2 + γδT-cells compared to NC subjects, without such differences for Vδ1 + γδT-cells (Fig 3C) . Furthermore, compared to uninfected control subjects, CHB subjects expressed less PD1, Tim3, CD38, Ki67 and CD158a but more NKG2A and CD94 in CD3 hi CD4 -Vδ2 + γδT-cells (Fig 2B and 2C) . Thus, circulating γδT-cells in AHB and CHB showed altered differentiation based on Tbet/Eomes expression, as well as activation through innate pathways involving NK receptors but not T-cell regulatory pathways including PD1. + γδT-cells increased between T1 and T2 in AHB but not CHB subjects.
https://doi.org/10.1371/journal.ppat.1007715.g009
Circulating gammadelta T cells in acute and chronic hepatitis B (Fig 3D) . Inverse associations between Tbet and PD1 as well as other co-inhibitory receptors have been reported in CD8 T-cells whereby Tbet mediates direct transcriptional repression of PD1 [79] . To our knowledge, similar associations between Tbet and PD-1 as well as other T/NK markers have not been reported in γδT-cells, but suggest a critical regulatory role for Tbet in γδT-cells. These broad and inter-related phenotypic alterations in circulating γδT-cells from AHB and CHB patients also suggest that γδT-cells participate in lymphocyte stress surveillance during HBV infection. Several new findings emerged in our study regarding γδT-cell function in HBV infection, despite different kinetics and strengths whereby Vδ2
+ γδT-cells were stimulated in-vitro by pAg (through the TCR) or non-specifically by PMA/Ionomycin (through protein kinase C and calcium signaling) [16, 26, 69, 80] [4] [5] [6] [7] [8] [9] , it was surprising that HBV DNA levels in CHB did not correlate with the circulating frequency or IFNγ/TNF expression by γδT-cells. This lack of correlation could reflect insufficient in-vivo activation of γδT-cells to exert antiviral activity (especially given increased expression of inhibitory NKG2A/CD94 receptors) although Vδ2 + γδT-cells from our CHB subjects were responsive to phosphoantigens in-vitro. In fact, circulating γδT-cells from CHB, NC and AHB subjects showed little to no cytokine expression when stained without further stimulation in-vitro (Figs 4B, 6A and 6B). As a caveat, it should be acknowledged that we did not study the intrahepatic compartment which is enriched in γδT-cells, although both Vδ1 + and Vδ2 + γδT-cells have been detected in the liver of HBV-infected and uninfected subjects [45, 85] . The inverse association between Vδ2 + γδT-cell function and ALT activity might also suggest a protective role for Vδ2 + γδT-cells against HBV-associated liver inflammation and hepatocellular injury. In fact, a late tissue protective and immune regulatory role have been suggested for γδT-cells, by directly killing activated macrophages, producing regulatory cytokines and secreting factors that promote tissue repair, beyond early pro-inflammatory effects [15, [86] [87] [88] [89] [90] . Consistent with this possibility, Vδ2 + γδT-cell depletion and anergy have been associated with adverse outcomes in HIV-infection [37] [38] [39] . Although beyond the scope of this study, potential regulatory roles in HBV pathogenesis have been suggested for γδT-cells with IFNγ-dependent suppression of Th17 + CD4 T-cells [45] and the induction of myeloidderived suppressor cells [49] . In this context, it is tempting to speculate if hepatitis flare in CHB might represent a failure of IFNγ−dependent regulatory function by Vδ2 + γδT-cells.
Alternatively, IFNγ/TNF deficit in Vδ2 + γδT-cells from CHB flare could be a consequence of inflammatory and regulatory mediators induced during active hepatocellular injury in-vivo [12, 91, 92] , as CHB flares are associated with necroinflammatory changes in the liver [71] [72] [73] . However, IFNγ/TNF expression by Vδ2 + γδT-cells did not improve even months after the resolution of CHB flare (including in one subject with therapeutic control of HBV DNA). In this regard, persistent IFNγ/TNF deficit in Vδ2 + γδT-cells from CHB Flare patients may represent continued cellular stress with fibrogenesis and cell turnover in the chronicallly HBV-infected liver despite apparent improvement in ALT, although we could not address this question due to limited number of liver biopsy in our study. By contrast, early IFNγ response to brief PMA/ Ionomycin stimulation improved in Vδ2 + γδT-cells from AHB subjects after 2-7 months from initial presentation, suggesting that regulatory effect on Vδ2 + γδT-cell function is reversible in AHB unlike CHB.
In conclusion, circulating γδT-cells are preserved in frequency and function, but with distinct and innate phenotype in acute and chronic HBV infection, with a significant inverse associations between early IFNγ/TNF responses in Vδ2 + γδT-cells and serum ALT in CHB.
Our findings suggest that circulating γδT-cells participate in lymphoid stress surveillance in HBV infection, with differential activation and differentiation with potential relevance to HBV pathogenesis. 
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